This website is intended for healthcare professionals from the United Kingdom only. Adverse event reporting information can be found at the bottom of the page.

Logo logo

INBRIJA® on-demand: Supporting patients when needed, up to 5 times per day1,2

Purple swoosh

INBRIJA® dosing is straightforward and can be administered on the go.1

  • One dose (84 mg) = two 42 mg capsules*
  • No more than 1 dose per OFF episode
  • May be taken as needed up to a maximum of 5 doses per day when symptoms start to return
  • Effective only in combination with CD/LD-based regimen
  • Capsules should be stored in their blister package and only removed immediately before use
  • INBRIJA® capsules are only for use with the INBRIJA® inhaler

Consent required
This content is provided by Vimeo. In order to display the embedded video, we need your consent. Please activate the Social Media Cookies to be able to play videos.
To find out more about how we process your data and use cookies please visit our privacy policy page.

This patient video helps to explain everything your patient needs to know about INBRIJA®. They can access it at inbrija.co.uk/patient.

*Each hard capsule contains 42 mg levodopa. Each delivered dose per capsule contains 33 mg levodopa.

References:

  1. 1. INBRIJA® Summary of Product Characteristics.
  2. 2. Safirstein BE et al., Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson’s disease. Clin Ther. 2020;42:1034-1046.
M-INB-UK-0050
Date of preparation: December 2025

This website contains information about INBRIJA® (levodopa inhalation powder)

I am a member of
the public

M-INB-UK-0047
Date of preparation: December 2025